Skip to main content
release_alert
Welcome to the new Scholars 3.0! Read about new features and let us know what you think.
cancel
Journal cover image

Hyperlactataemia syndromes associated with HIV therapy.

Publication ,  Journal Article
Ogedegbe, AEO; Thomas, DL; Diehl, AM
Published in: Lancet Infect Dis
June 2003

Hyperlactataemia is seen in 8-18.3% of HIV-infected patients taking nucleoside-analogue reverse transcriptase inhibitors (NRTIs). Recent epidemiological studies suggest that most episodes are transient and subclinical. However, symptomatic and occasionally life-threatening cases accompanied by metabolic acidosis and hepatic steatosis (ie, lactic acidosis syndrome) have also been described. Though yet to be fully elucidated, the proposed mechanism is NRTI-induced inhibition of mitochondrial DNA polymerase culminating in derangements in oxidative phosphorylation and lactate homeostasis. Signs and symptoms range from mild hyperlactataemia accompanied by nausea, abdominal discomfort, and weight loss to severe, intractable lactic acidosis complicated by coma and multi-organ failure. Significant progress has recently been made with regard to the natural history of NRTI-related hyperlactataemia. However, other important aspects of the disorder, such as its pathogenesis, predisposing conditions, and management, remain poorly understood. This article reviews the current published work on these issues, identifies areas of controversy, and addresses directions for future research.

Duke Scholars

Published In

Lancet Infect Dis

DOI

ISSN

1473-3099

Publication Date

June 2003

Volume

3

Issue

6

Start / End Page

329 / 337

Location

United States

Related Subject Headings

  • Syndrome
  • Reverse Transcriptase Inhibitors
  • Microbiology
  • Humans
  • HIV Infections
  • Anti-HIV Agents
  • Acidosis, Lactic
  • 1117 Public Health and Health Services
  • 1108 Medical Microbiology
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ogedegbe, A. E. O., Thomas, D. L., & Diehl, A. M. (2003). Hyperlactataemia syndromes associated with HIV therapy. Lancet Infect Dis, 3(6), 329–337. https://doi.org/10.1016/s1473-3099(03)00654-6
Ogedegbe, Anthony Emmanuel O., David L. Thomas, and Anna Mae Diehl. “Hyperlactataemia syndromes associated with HIV therapy.Lancet Infect Dis 3, no. 6 (June 2003): 329–37. https://doi.org/10.1016/s1473-3099(03)00654-6.
Ogedegbe AEO, Thomas DL, Diehl AM. Hyperlactataemia syndromes associated with HIV therapy. Lancet Infect Dis. 2003 Jun;3(6):329–37.
Ogedegbe, Anthony Emmanuel O., et al. “Hyperlactataemia syndromes associated with HIV therapy.Lancet Infect Dis, vol. 3, no. 6, June 2003, pp. 329–37. Pubmed, doi:10.1016/s1473-3099(03)00654-6.
Ogedegbe AEO, Thomas DL, Diehl AM. Hyperlactataemia syndromes associated with HIV therapy. Lancet Infect Dis. 2003 Jun;3(6):329–337.
Journal cover image

Published In

Lancet Infect Dis

DOI

ISSN

1473-3099

Publication Date

June 2003

Volume

3

Issue

6

Start / End Page

329 / 337

Location

United States

Related Subject Headings

  • Syndrome
  • Reverse Transcriptase Inhibitors
  • Microbiology
  • Humans
  • HIV Infections
  • Anti-HIV Agents
  • Acidosis, Lactic
  • 1117 Public Health and Health Services
  • 1108 Medical Microbiology
  • 1103 Clinical Sciences